John Frantzis (l) and Alex Lopez.

BOSTON—Ace Vision Group, Inc. (AVG), a privately held U.S. ophthalmic medical device company developing laser microporation therapeutic technologies to treat diseases of the aging eye, announced the appointment of John Frantzis as chief business development officer and Alex Lopez as chief commercial officer. "Our team is ecstatic to have such notable and experienced strategic leaders in the ophthalmic industry joining Ace Vision Group at this stage of the company's journey," said AnnMarie Hipsley, DPT, PhD, founder and CEO of AVG.

"I have great respect for the accomplishments of both John Frantzis and Alex Lopez in each of their long-standing careers in health care. I am eager to see their impact on AVG's commercial strategy and success. Building an impeccable executive leadership of C-level talent will contribute immeasurably to AVG's continual growth toward commercialization of our flagship technology, the VisioLite Ophthalmic Laser System and the Laser Scleral Microporation (LSM) procedure.”

As chief business development officer, Frantzis will lead AVG 's strategic venture capital funding efforts, global business development, distribution and sales. Frantzis has more than 25 years of executive management experience in emerging technologies with expertise in producing high growth and results driven products in the biotech and pharmaceutical spaces.

"The VisioLite Ophthalmic Laser System is the most innovative technology I have seen in the last 20 years. LSM therapy has the potential to have a significant impact on the presbyopia market, which is the largest market opportunity in ophthalmology with limited available treatment options," said Frantzis. "I am honored to be part of the AVG team and playing a role in introducing a revolutionary therapy such as LSM into the ophthalmic market."

Lopez brings more than two decades of experience in the eyecare industry to AVG. In his new role as chief commercial officer, Lopez will be responsible for the commercial launch of AVG's technology platform, the VisioLite Laser and the LSM therapeutic procedure.

Lopez said, "I am excited to be working with such an inventive group and bringing innovative technology to market that has the potential to change the presbyopia standard of care. This is a great opportunity to create a new recurring revenue category for ophthalmologists, while providing patients with a higher level of care with the first in-office therapeutic treatment for the presbyopic patient. My long-standing experience in ophthalmology combined with my experience in aesthetics is perfectly suited to support the corporate and commercial vision of AVG."